MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Free Cash flow
-$8,770,577
Unit: Dollar
Positive Cash Flow Breakdown
Proceeds from revolving credit f...
Stock compensation expense
Proceeds from issuance of common...
Others
Negative Cash Flow Breakdown
Net loss
Accounts payable and accrued exp...
Payment of placement agent fees ...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-9,223,298
-7,536,598
-6,761,316
-7,102,455
Stock compensation expense
2,143,234
2,796,240
2,147,467
1,445,480
Depreciation and amortization
28,104
23,472
22,544
21,292
Amortization of debt discount
-
-
481,424
-
Loss on share settlement of kineta employee compensation assumed from merger
-
-
-
185,019
Loss on share issuance to kineta separation payments
-
-
185,019
-
Change in fair value of kineta merger holdback shares
-
-
-
315,660
Change in fair value of holdback shares
-
-
-1,590,948
-
Amortization of deferred loan costs
295,290
-
-
-
Other current assets
-24,266
182,970
-124,446
-222,659
Other noncurrent assets
-38,867
-34,897
-185,574
-39,804
Accrued interest
-172,344
-
-
-
Accounts payable and accrued expenses
-2,112,406
452,006
150,447
-6,214,003
Net cash flows from operating activities
-8,633,599
-4,412,953
-5,556,022
-11,086,544
Cash paid for kineta acquisition, net of assumed cash
-
-
0
0
Purchase of property and equipment
136,978
48,846
27,850
0
Net cash flows from investing activities
-136,978
-48,846
-27,850
0
Cash dividend payment of preferred stock series a
2,089
2,089
2,089
2,089
Repayment of assumed kineta indeptedness
-
-
0
434,000
Proceeds from bridge note
-
-
3,000,000
-
Proceeds from revolving credit facility
3,600,000
-
-
-
Proceeds from warrants exercised
-
-
0
0
Payment of bridge note
-
-
1,401,323
98,677
Payment of revolving credit facility debt issuance costs
202,450
-
-
-
Payment of offering costs associated with issuance of common stock
-
-
1,223,944
-
Proceeds from issuance of common stock
311,024
7,500,000
6,191,140
6,197,547
Payment of merger transaction costs
-
-
0
0
Payments made on kineta severance promissory notes
0
197,354
394,709
-
Principal payments of finance lease
11,050
10,845
10,644
43,671
Payment of placement agent fees and offering costs
227,008
-529,602
-
679,337
Payment of net liabilities assumed in reverse recapitalization
-
-
0
0
Net cash flows from financing activities
3,468,427
7,139,977
6,506,405
5,271,136
Net change in cash and cash equivalents
-5,302,150
2,678,178
922,533
-5,815,408
Cash and cash equivalents at the beginning of the period
6,298,127
3,619,949
2,697,416
12,657,178
Cash and cash equivalents at the end of the period
995,977
6,298,127
3,619,949
2,697,416
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from revolving
credit facility
$3,600,000
Proceeds from issuance of
common stock
$311,024
(-94.74%↓ Y/Y)
Net cash flows from
financing activities
$3,468,427
(-57.44%↓ Y/Y)
Canceled cashflow
$442,597
Net change in cash
and cash...
-$5,302,150
(-27.94%↓ Y/Y)
Canceled cashflow
$3,468,427
Stock compensation
expense
$2,143,234
(-24.32%↓ Y/Y)
Amortization of deferred loan
costs
$295,290
Accrued interest
-$172,344
Other noncurrent
assets
-$38,867
(-155.22%↓ Y/Y)
Depreciation and
amortization
$28,104
(2.46%↑ Y/Y)
Other current assets
-$24,266
(78.02%↑ Y/Y)
Payment of placement
agent fees and...
$227,008
Payment of revolving
credit facility debt...
$202,450
Principal payments of
finance lease
$11,050
Cash dividend
payment of preferred...
$2,089
(-50.00%↓ Y/Y)
Net cash flows from
operating activities
-$8,633,599
(21.42%↑ Y/Y)
Canceled cashflow
$2,702,105
Net cash flows from
investing activities
-$136,978
(89.52%↑ Y/Y)
Net loss
-$9,223,298
(43.02%↑ Y/Y)
Accounts payable and
accrued expenses
-$2,112,406
(-191.75%↓ Y/Y)
Purchase of property and
equipment
$136,978
(183.99%↑ Y/Y)
Buy us a coffee
TuHURA Biosciences, Inc. NV (HURA)
TuHURA Biosciences, Inc. NV (HURA)